Comparative Pharmacology
Head-to-head clinical analysis: BUCAPSOL versus DIMETHYL SULFOXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUCAPSOL versus DIMETHYL SULFOXIDE.
BUCAPSOL vs DIMETHYL SULFOXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BUCAPSOL (bupivacaine liposome) is a long-acting local anesthetic. Bupivacaine acts by binding to the intracellular portion of voltage-gated sodium channels, thereby blocking nerve signal propagation. The liposomal formulation provides sustained release.
Dimethyl sulfoxide (DMSO) is a polar aprotic solvent that penetrates biological membranes, scavenges hydroxyl radicals, and stabilizes lysosomal membranes. It has anti-inflammatory, analgesic, and cryoprotective properties. It enhances cutaneous absorption of other drugs and induces histamine release from mast cells, causing vasodilation and urticaria.
BUCAPSOL (buspirone hydrochloride) 5 mg orally three times daily; may increase by 5 mg every 2-3 days to a maximum of 60 mg/day.
50% solution topically applied every 6 hours; intravenous: 0.5-1 g/kg as a 10-20% solution over 30-60 minutes every 6 hours for 3-5 doses
None Documented
None Documented
Clinical Note
moderateDimethyl sulfoxide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide."
Clinical Note
moderateDimethyl sulfoxide + Atorvastatin
"The risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin."
Clinical Note
moderateDimethyl sulfoxide + Dexrazoxane
"The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide."
Clinical Note
moderateTerminal half-life 12–15 hours; prolonged in renal impairment (up to 30 hours)
Terminal half-life: 11-14 hours for DMSO; DMSO2 half-life 60-70 hours, accumulates with repeated dosing. Clinical context: renal impairment prolongs half-life.
Renal 70% as unchanged drug, biliary/fecal 15% as metabolites, 15% other
Renal: 30-50% unchanged; hepatic metabolism to dimethyl sulfone (DMSO2) and dimethyl sulfide (DMS); DMSO2 excreted renally, DMS exhaled; fecal elimination <5%.
Category C
Category C
Topical Analgesic
Topical Analgesic
Metoprolol + Dimethyl sulfoxide
"The serum concentration of Dimethyl sulfoxide can be increased when it is combined with Metoprolol."